🇺🇸

Distress Insolvency

US SEC Filing Intelligence · 108 digests

· daily

US Corporate Distress Financial Stress SEC Filings — July 02, 2026

The 50 filings reveal a pronounced bifurcation in corporate health: while several companies are securing substantial capital (BridgeBio $1B, NextDecade $3.5B, Neurogene $134.8M) and extending credit lines (Haverty +$20M, Cheniere +$500M), a cluster of distressed firms are fighting for survival through high-cost debt (American Rebel 36.6% effective rate), repeated maturity extensions (CareView 15th amendment), and reverse stock splits (Snail 1-for-5). Distress signals dominate: 5 companies received Nasdaq deficiency notices (RenovoRx, HeartBeam, ALT5 Sigma, Boxlight, Snail), 1 approved liquidation (Origin Materials), and 1 faces delisting (Boxlight). Period-over-period data is sparse but shows HUMBL's revenue growing 20% YoY while losses widen, and Centrus Energy securing a $900M DOE contract but with first capacity not until 2029. Insider activity is limited but includes CEO Nicholas Liuzza receiving shares at a premium in Beeline Holdings. The overarching theme is capital access as a differentiator—well-capitalized firms are investing for growth, while cash-strapped firms resort to dilutive or expensive financing.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 01, 2026

This digest of 50 pre-analyzed SEC filings from July 1, 2026, reveals a pronounced bifurcation in corporate health. On one side, a wave of distress signals is concentrated among small-cap and micro-cap companies, with 8 filings directly involving bankruptcy, going concern, delisting, or severe liquidity crises. These include InnSuites Hospitality Trust (IHT) receiving a delisting notice due to a stockholders' deficit, Stratus Properties (STRS) voluntarily liquidating, and multiple companies like Nuvve (NVVE) and Trio Petroleum executing reverse splits or taking on high-interest debt. Conversely, a separate cohort of larger, more established firms is proactively strengthening their balance sheets and extending maturities, exemplified by Peabody Energy (BTU) upsizing and extending its credit facility, FTI Consulting (FCN) increasing its revolver to $1.5B, and Kohl's (KSS) extending its facility by five years. A third theme is the aggressive use of dilutive financing, particularly through convertible notes and equity lines, by companies like HIVE Digital, Energy Vault, and OneMedNet, signaling a 'growth at all costs' or 'survival financing' strategy. The overall picture is one of a market where access to cheap capital is highly uneven, creating both acute risks and selective opportunities in distressed assets and well-capitalized survivors.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 30, 2026

This digest of 50 SEC filings reveals a pronounced theme of corporate distress and strategic restructuring across US public companies. A significant cluster of firms are actively managing liquidity and leverage through debt refinancing, asset sales, and equity offerings, often under duress. Key period-over-period trends include tightening financial covenants (e.g., HighPeak Energy's leverage ratio step-down) and a shift towards dilutive financing (e.g., Quantum Computing's authorized share increase, Eos Energy's rights offering). The most critical developments are multiple Nasdaq delisting warnings (Gulf Resources, SolarMax Technology) and a high volume of distressed asset sales (Sadot Group, Advanced Biomed) for nominal cash, signaling severe financial strain. A portfolio-level pattern is the reliance on single-lender credit facilities and complex, contingent financing structures, which introduce significant execution risk.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 29, 2026

This digest reveals a bifurcated corporate landscape on June 29, 2026, where aggressive M&A and financing activity (e.g., Martin Marietta's $13.5B acquisition, Rocket Lab/Iridium $8B merger) coexists with acute distress signals from micro-cap companies resorting to dilutive offerings and asset sales. The most critical theme is the 'cash-for-survival' pattern: multiple distressed entities (Volato, Datavault AI, U.S. GoldMining) are executing deeply dilutive financings or selling digital assets at a loss to stave off insolvency, while healthier firms are using cheap debt to consolidate. A notable period-over-period trend is the compression of margins in capital-intensive sectors (Honeywell Aerospace Q4 net income down 25% YoY) contrasted with high-margin recurring revenue models (Iridium's 57% OEBITDA margin). Insider activity is sparse but telling, with director resignations at Volato signaling governance risk. The forward-looking catalyst calendar is dense with Q3 2026 merger closes (TOMI/Carbonium, SandRidge, Martin Marietta) and a major mid-2027 close for the Rocket Lab/Iridium deal, creating a 12-month arbitrage window. The overarching takeaway: the market is rewarding scale and recurring cash flow while punishing companies with weak balance sheets and no clear path to profitability.

45 high priority 45 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 26, 2026

The 42 filings from June 26, 2026, paint a stark picture of corporate distress across the US public markets, with a heavy concentration of liquidity crises, covenant breaches, dilutive financing, and active bankruptcy proceedings. A dominant theme is the aggressive use of high-cost, convertible debt and preferred stock to stave off collapse, as seen at VEEA, Mobix Labs, and CERO Therapeutics, which are trading near-term liquidity for massive future dilution. Multiple companies, including Hallador Energy and RMX Industries, have secured covenant relief or maturity extensions from lenders, signaling acute financial pressure. The distress is sector-agnostic, hitting biotech (Matinas BioPharma, HCW Biologics), energy (Hallador), and technology (Upexi, SmartKem) alike. However, a notable counter-trend exists where fundamentally sound companies are executing strategic refinancings (Oceaneering, California Resources) or transformative M&A (H.B. Fuller, Bristow Group), indicating a bifurcated market where capital is available for strong credits but prohibitively expensive for the weak. The period-over-period data reveals a clear pattern of deteriorating equity bases, repeated covenant violations, and a reliance on insider-related financing as a last resort.

42 high priority 42 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 26, 2026

This digest of 42 SEC filings reveals a surge in corporate distress signals, particularly among small-cap life sciences and technology companies. The most critical developments include a Nasdaq delisting notice for Upexi, a second NYSE non-compliance notice for Matinas BioPharma, and a Chapter 11 overbid agreement for Charles & Colvard, indicating severe liquidity crises. A dominant theme is covenant-relief amendments, with Hallador Energy and RMX Industries securing breathing room from lenders, signaling financial strain. Conversely, a wave of opportunistic capital raising is underway, with ADP securing a $5.7B credit facility and Venture Global closing a $1.5B vessel financing, highlighting a bifurcated market where strong companies access cheap capital while distressed firms rely on dilutive or high-cost financing. Insider activity is limited, but the conversion of $4.1M in CEO debt to equity at Veea and the dilutive terms of Cero Therapeutics' note suggest management is using insider structures to manage cash burn. Forward-looking data points to a catalyst-rich period, with key data readouts from Vaxart and a merger deadline for Graf Global approaching in the coming weeks.

42 high priority 42 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 25, 2026

The June 25, 2026, filing batch reveals a bifurcated corporate landscape: while several companies are successfully accessing capital markets (Robinhood's $2.2B zero-coupon note, SharonAI's $1.6B raise) and executing strategic M&A (onsemi's $7B acquisition of Synaptics, PetVivo's acquisition of PiezoBioMembrane), a significant cohort is exhibiting acute distress signals. Multiple companies are teetering on the brink of bankruptcy or delisting, evidenced by Americas CarMart's waiver of anticipated defaults with a September 2026 deadline, Heron Therapeutics' Nasdaq bid price deficiency, and the high-risk 12% coupon on New Fortress Energy's Brazilian notes. The period-over-period data, where available, shows a stark contrast: Blue Owl Real Estate's 15% YoY revenue growth is overshadowed by an 87.5% decline in net realized gains, while Aytu BioPharma's Metadate CD product generated only $49,000 in quarterly revenue before its license was terminated. A critical theme is the prevalence of related-party and insider transactions (DSS/Alset, TerrAscend) that raise governance concerns, particularly as companies seek emergency financing. The overall sentiment is mixed, with a clear divergence between well-capitalized firms pursuing growth and cash-strapped entities fighting for survival.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 24, 2026

The 50 filings reveal a bifurcated corporate landscape on June 24, 2026, with acute distress signals concentrated in micro-cap and pre-revenue biotech/tech companies, while larger, established firms engage in routine capital management. The most critical developments include the imminent delisting of Aditxt (ADTX) and the high-risk reverse split at SRx Health Solutions (SRXH), both representing terminal distress. A significant theme is the aggressive use of reverse stock splits and dilutive financing by cash-strapped companies to maintain exchange listings, a pattern that has historically failed. Conversely, several companies are executing strategic pivots: Comstock Inc. sold legacy mining assets for $45M+ to focus on renewable metals, and Hyperscale Data secured a $1.2B+ AI compute contract, signaling a shift from crypto to AI infrastructure. The data also shows a wave of SPAC activity (Churchill Capital XI, Gores Holdings XI, Wilco 63) targeting AI and robotics, indicating strong market appetite for exposure to these themes. Period-over-period data, where available, shows revenue growth at Worksport (+47.9% YoY) and margin improvement, but this is overshadowed by the company's cash flow negativity. The overarching theme is a 'survival of the fittest' dynamic where companies with clear strategic direction and access to capital are thriving, while those with weak fundamentals and repeated compliance failures are facing extinction.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 23, 2026

The June 23, 2026, digest reveals heightened corporate distress across several US public companies, with two bankruptcy filings (Sangamo Therapeutics, Office Properties Income Trust) and multiple pre-bankruptcy distress signals including dilutive financings, delistings, and going concern warnings. A significant cluster of severe dilution events—notably AMC Entertainment raising $200M at a 19% discount, SharpLink Gaming diluting shareholders by 10M shares, and CIMG Inc.'s potentially catastrophic 43.3 billion share issuance—indicate acute liquidity crises among small/mid-cap firms. The period-over-period trends show a troubling pattern of 'distressed liability management,' where companies are trading equity for debt reduction or operating capital at depressed valuations. The credit markets present a bifurcated picture: blue-chip companies (IBM, PG&E, Fiserv) are easily refinancing at improved terms, while distressed issuers (Jack in the Box, Beazer Homes) face punitive rates (7.6% vs 4.5% prior). The most critical development is Sangamo's Chapter 11 filing, which serves as a bellwether for the biotech sector's ongoing cash crunch.

40 high priority 40 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — June 23, 2026

The June 23, 2026 bankruptcy/insolvency landscape is dominated by two distinctly structured restructurings: a completed Chapter 11 emergence (Office Properties Income Trust) and a new Chapter 11 filing with asset sales (Sangamo Therapeutics). OPIRQ's emergence involves complex tax gearing—massive cancellation of debt (COD) income offsetting NOLs and creating a NUBIL—which could pressure REIT qualification and future distributable income. Sangamo's filing triggers a stalking horse sale of core assets to Eli Lilly and Astellas for $75M+ in upfront/milestone payments, coupled with a $30M DIP facility, implying an imminent liquidation/run-off. Both filings reveal a sector theme of resource-constrained companies monetizing tax attributes (OPIRQ) or intellectual property (Sangamo) to satisfy creditors, with material insider trading signals notably absent, suggesting management teams are already disengaged or locked up post-restructuring. The combined period-over-period data is sparse due to the event-driven nature, but the forward-looking guidance hints at constrained operations for OPIRQ and a wind-down for Sangamo.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 22, 2026

Today's filings reveal a significant uptick in distress signals across micro-cap companies, with going concern risks, repeated defaults, and emergency equity offerings dominating the landscape. We see four companies in active liquidity crises (Algorhythm Holdings, Sable Offshore, Exyn Technologies) or warning of going concern uncertainty (CervoMed), while several others are forced to issue highly dilutive convertible notes or sell stock at deep discounts. A sharp bifurcation is evident: large-cap M&A (CRH/Arcosa, AbbVie/Apogee, Booz Allen) provides a bright spot, but for smaller firms, cash preservation through debt renegotiation, asset subleasing, and insider-funded advances is the prevailing theme. The average sentiment across all filings is neutral-to-mixed, with no sector-wide positive trends emerging in period-over-period comparisons as most filings lacked quantitative revenue or margin data. Key actionable insights include betting on the acquirers (CRH, AbbVie) and avoiding the most distressed micro-caps.

41 high priority 41 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 18, 2026

This digest covers 50 filings from June 18, 2026, revealing a pronounced bifurcation in corporate health. A clear theme is the aggressive use of capital markets by distressed companies to stave off insolvency, with 6 at-the-market (ATM) offerings and 3 private placements totaling over $500 million in potential dilution. Conversely, several firms are successfully refinancing debt on favorable terms, extending maturities by 2-4 years and improving balance sheet flexibility. The most critical distress signals are concentrated in micro-cap and pre-revenue biotech/tech companies, with 2 Nasdaq delisting notices (Dyadic International, Algorhythm Holdings) and one terminated SPAC merger (Papaya Growth Opportunity Corp. I). A notable sector theme is the high cost of distress financing, with companies like Nuvve Holding and CoreWeave agreeing to interest rates of 39% and 9.625% respectively, highlighting a two-tiered credit market. Insider trading data was sparse across these filings, but the prevalence of dilutive financing structures (convertible notes, preferred stock exchanges) signals significant shareholder value destruction for existing holders in distressed names.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 17, 2026

The 45 filings reveal a bifurcated corporate distress landscape: several companies face acute bankruptcy/delisting risks (Sleep Number, Vestand, Workhorse, Gencor) while others execute strategic refinancings or M&A to strengthen balance sheets (Dyne Therapeutics, Kilroy Realty, HEICO). Notable period-over-period trends include margin compression in office REITs (Kilroy occupancy 77.6%) and revenue growth in licensing (Playboy Q1 2026 Adjusted EBITDA doubled YoY). Insider activity is sparse but includes a significant share repurchase from a departing chairman (South Plains Financial). Capital allocation patterns show a shift toward debt reduction (Playboy $52M earmarked) and equity-linked financing (iQSTEL 24% preferred, AIxCrypto 93% VWAP). The most critical developments are Sleep Number's Chapter 11 delisting and Bed Bath & Beyond's transformative acquisition of Fathom Holdings, signaling potential value creation or further distress. Portfolio-level patterns include a wave of credit facility amendments (10+ filings) and reverse stock splits (Allurion) as companies manage liquidity.

45 high priority 45 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 16, 2026

This batch of 36 filings paints a stark picture of corporate distress, with a surge in bankruptcy filings and liquidity-driven restructuring. Sleep Number Corp's Chapter 11 filing and FiscalNote's debt waiver request are the most acute distress signals, while companies like CEL-SCI and LIXTE Biotechnology (via a reverse merger) highlight the desperation for capital and strategic pivots. There is a clear bifurcation in the credit markets: highly distressed firms are diluting equity and restructuring debt, while healthier companies (Rocket, Dell, Matador) are proactively refinancing at longer maturities, albeit often at higher rates. The most actionable intelligence centers on a wave of M&A as both a distress exit (Open Lending) and a capital allocation strategy (Yum! Brands/China, Olin/Huntsman), but investors must beware the significant execution and integration risks flagged in several deals. Notably, period-over-period comparisons are sparse in these event-driven filings, but the presence of debt-for-equity swaps, distressed asset sales (Bright Mountain Media), and dependence on novel financing (Applied Digital's AI data center build-out) are all high-risk patterns demanding close monitoring.

36 high priority 36 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 15, 2026

The 50 filings from June 15, 2026, paint a picture of a market bifurcated between aggressive corporate restructuring and strategic M&A. A dominant theme is the use of high-yield debt and convertible notes to refinance or raise capital, with several companies (Owens & Minor, Jack in the Box, Cipher Mining) issuing new notes at significantly higher interest rates (7.6% to 9.75%) to replace lower-coupon debt, signaling increased leverage costs. Concurrently, there is a wave of major M&A and divestiture activity, including Fox's $22B acquisition of Roku, Nuvei's $2.75B purchase of Payoneer, and Comtech's $157.5M segment sale, indicating sector consolidation. Distress signals are also prominent, with three companies (Functional Brands, ESS Tech, Momentus) facing delisting or NYSE non-compliance, and several others (Healthcare Triangle, Zeo Energy) engaging in highly dilutive, high-cost financing. Insider activity is sparse but notable, with a debt-to-equity conversion by insiders at RenX Enterprises. The overall sentiment is mixed, with a clear divergence between well-capitalized firms executing strategic moves and distressed entities fighting for survival.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 12, 2026

This digest of 50 US SEC filings from June 12, 2026, reveals a pronounced wave of corporate distress, particularly among small-cap and micro-cap companies. The most critical theme is a cluster of bankruptcy, delisting, and going-concern warnings, with Sleep Number Corp's Chapter 11 filing being the most severe event, signaling a complete loss for common equity holders. A secondary theme is the aggressive use of high-cost, dilutive financing (convertible notes, ATM offerings, and secured loans with interest rates up to 16%) by cash-strapped companies like BioRestorative Therapies, Genasys, and Edible Garden AG, indicating severe liquidity constraints. Conversely, a few larger entities like Super Micro Computer and Delta Air Lines are accessing capital markets on favorable terms for growth and refinancing, highlighting a bifurcated market where access to capital is a key differentiator. The data shows a high frequency of Nasdaq deficiency notices (Soligenix, La Rosa, Genprex, etc.), suggesting a systemic issue with micro-cap listed companies failing to meet minimum listing standards. Insider activity is limited but telling, with director resignations at BioRestorative Therapies coinciding with a lender-forced board change, a classic distress signal. Forward-looking statements are predominantly negative, with multiple companies disclosing uncertain futures, ongoing negotiations with lenders, and strategic alternatives evaluations.

50 high priority 50 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — June 12, 2026

The sole filing in this session is a high-materiality Chapter 11 filing from Sleep Number Corp (SNBR), which has entered a 363 sale process with Sleep Country Canada as the stalking horse bidder. The company secured up to $260M in DIP financing (including $65M new money) to maintain operations across 570+ stores during the proceedings. However, the purchase price is expected to render common equity worthless, and the company has already moved to reject leases on 44 non-operational locations. This filing signals a definitive end for equity holders and a structured exit via asset sale, with no period-over-period comparisons or insider activity data available to assess prior trends. The key theme is a distressed retail bankruptcy with a pre-arranged stalking horse, limiting upside for unsecured creditors and equity but providing operational continuity for the business.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 11, 2026

The 41 filings from June 11, 2026, paint a picture of a market with significant capital churn and distress signals, particularly in the small-cap and pre-revenue biotech sectors. A dominant theme is the aggressive use of equity-linked financing (convertible notes, PIPEs, equity lines) by cash-burning companies like PureCycle, AIM ImmunoTech, and Atossa Therapeutics, signaling ongoing liquidity pressure. Conversely, several energy and industrial firms (Presidio Production, Venture Global, AECOM) are successfully refinancing debt at lower costs, indicating a bifurcation between distressed and healthy balance sheets. The most critical development is the Chapter 11 filing and Nasdaq delisting of GoHealth, a high-materiality event that underscores the risks in the insurtech space. Portfolio-level trends show a clear pattern of distressed companies using reverse stock splits (Verano, Shuttle Pharma) to maintain listing compliance, while larger firms (Ciena, IQVIA) execute large-scale debt offerings for refinancing and strategic purposes. Insider activity is limited in these filings, but the CEO-led PIPE at Edesa Biotech provides a positive signal, contrasting with the general lack of insider buying in most distressed issuers.

41 high priority 41 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 10, 2026

This intelligence stream reveals a bifurcated corporate landscape: while capital-intensive sectors like data centers and AI infrastructure are attracting massive debt financing (e.g., Hut 8's $4.25B notes, Amazon's $17.5B loan), a parallel wave of distress is sweeping through smaller, cash-burning entities. The most critical theme is a surge in dilutive financing and costly debt restructurings, with 8 companies engaging in equity or convertible offerings and 3 companies executing high-interest refinancings (B&G Foods at 11.00%, Pacific Oak at 11.5%). Period-over-period data, though limited in this batch, shows margin compression at TPG Twin Brook (ROE down 80 bps YoY) and a clear pattern of companies trading financial health for survival. Insider activity is notably absent, but management actions—like Aditxt spinning off a subsidiary at a $150M valuation while the parent struggles—signal a 'hive-off' strategy to unlock value. The forward-looking data is dominated by catalyst dates (hearings, offering closings) that will determine the fate of several distressed names, making the next two weeks critical for portfolio positioning.

37 high priority 37 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 09, 2026

The 32 filings reveal a bifurcated landscape: robust M&A activity (Nuvalent, Novanta, Ingredion, Cycurion) and capital markets access (Arch Capital, Cheniere, PennantPark) contrast sharply with distress signals from micro-cap companies facing Nasdaq non-compliance, dilutive financings, and cash burn. Period-over-period data shows mixed trends—Soluna's 58% YoY revenue growth and record hash rate contrast with NexPoint's declining Core FFO and margin compression. Insider activity is limited, but debt-to-equity conversions (Rain Enhancement) and PIPE deals (HWH International) indicate financial strain. Key themes include healthcare/biotech M&A at premium valuations, energy infrastructure debt issuance, and a wave of reverse stock splits and going concern warnings among small caps. The most critical developments are the $10.6B Nuvalent acquisition, Ingredion's $5.0B Tate & Lyle bid, and multiple Nasdaq deficiency notices (Professional Diversity Network, Jasper Therapeutics).

32 high priority 32 total filings